Search results for "DM"

showing 10 items of 8932 documents

Score to identify the severity of adult patients with influenza A (H1N1) 2009 virus infection at hospital admission

2012

The objective of this paper was to develop a prognostic index for severe complications among hospitalized patients with influenza A (H1N1) 2009 virus infection. We conducted a prospective observational cohort study of 618 inpatients with 2009 H1N1 virus infection admitted to 36 Spanish hospitals between July 2009 and February 2010. Risk factors evaluated included host-related factors and clinical data at admission. We developed a composite index of severe in-hospital complications (SIHC), which included: mortality, mechanical ventilation, septic shock, acute respiratory distress syndrome, and requirement for resuscitation maneuvers. Six factors were independently associated with SIHC: age >…

AdultMaleMicrobiology (medical)medicine.medical_specialtyChronic Obstructive Pulmonary DiseaseComorbiditymedicine.disease_causeSeverity of Illness IndexArticleBody Mass IndexSeasonal InfluenzaInfluenza A Virus H1N1 SubtypePregnancyRisk FactorsInternal medicineInfluenza HumanSeverity of illnessOdds RatiomedicineInfluenza A virusHumansIntensive Care Unit AdmissionProspective StudiesProspective cohort studyAgedRespiratory Distress SyndromeFramingham Risk ScoreSeptic shockbusiness.industryComputational BiologyGeneral MedicineOdds ratioMiddle AgedPrognosismedicine.diseaseRespiration ArtificialShock SepticInfluenzaSurgeryHospitalizationPneumoniaInfectious DiseasesROC CurveCase-Control StudiesMultivariate AnalysisFemaleInfluenza EpidemicbusinessCohort studyEuropean Journal of Clinical Microbiology & Infectious Diseases
researchProduct

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter p…

2010

Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poor prognosis. First-line systemic treatments in advanced disease include mitotane, either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed the activity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavily pretreated advanced ACC patients. From 1998 to 2008, 28 patients with advanced ACC progressing after mitotane plus one or two systemic chemotherapy lines were enrolled. They received a combination of i.v. gemcitabine (800 mg/m2, on days 1 and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (2…

AdultMaleMucositisOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyAdrenocortical carcinomaSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhases of clinical researchDeoxycytidineGastroenterologyDrug Administration ScheduleCapecitabineEndocrinologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansMitotaneCapecitabineAgedChemotherapybusiness.industryLeukopeniaMiddle Agedmedicine.diseaseThrombocytopeniaGemcitabineAdrenal Cortex NeoplasmsGemcitabineRegimenTreatment OutcomeOncologyFluorouracilDisease ProgressionFemaleFluorouracilbusinessmedicine.drug
researchProduct

Treadmill versus overground and barefoot versus shod comparisons of triceps surae fascicle behaviour in human walking and running

2013

Studies of human locomotion are commonly performed on a treadmill or overground, as well as with or without footwear. These testing modalities have been suggested to influence kinematics, kinetics and/or spatio-temporal variables differently. However, it is unclear whether they influence contractile behaviour at the level of the muscle fascicles. This has major relevance because results from studies performed with different combinations of the testing modalities are often compared. The present study used ultrasound to examine fascicle behaviour of the medial gastrocnemius (MG) and soleus muscles of ten young, healthy males during walking and running on a treadmill and overground, as well as…

AdultMaleMuscle fasciclemedicine.medical_specialtyLower velocityBiophysicsWalkingRunningBarefootGait (human)medicineHumansOrthopedics and Sports MedicineTreadmillMuscle Skeletalta315Human locomotionUltrasonographybusiness.industryRehabilitationFascicleBiomechanical PhenomenaShoesKineticsmedicine.anatomical_structureExercise TestPhysical therapymedicine.symptombusinessMuscle ContractionMuscle contractionGait & Posture
researchProduct

Maintenance treatment for opioid dependence with slow‐release oral morphine: a randomized cross‐over, non‐inferiority study versus methadone

2012

Aims To compare the efficacy of slow-release oral morphine (SROM) and methadone as maintenance medication for opioid dependence in patients previously treated with methadone. Design Prospective, multiple-dose, open label, randomized, non-inferiority, cross-over study over two 11-week periods. Methadone treatment was switched to SROM with flexible dosing and vice versa according to period and sequence of treatment. Setting Fourteen out-patient addiction treatment centres in Switzerland and Germany. Participants Adults with opioid dependence in methadone maintenance programmes (dose ≥50 mg/day) for ≥26 weeks. Measurements The efficacy end-point was the proportion of heroin-positive urine samp…

AdultMaleNarcoticsMethadone maintenanceretention ratePopulationslow-release oral morphineAdministration OralMedicine (miscellaneous)Maintenance ChemotherapyMedication AdherencemethadoneOpiate Substitution TreatmentmedicineHumanseducationMorphine Derivativeseducation.field_of_studyCross-Over StudiesMorphinemaintenance treatmentCodeinebusiness.industryCodeineResearch ReportsOpioid use disorderOpiate Substitution TreatmentMiddle AgedOpioid-Related Disordersmedicine.diseaseCrossover studyPsychiatry and Mental healthTreatment OutcomeOpioidDelayed-Action PreparationsAnesthesiaFemaleDose–responsebusinessopioid addictionMethadonemedicine.drugAddiction
researchProduct

Desmopressin in the Treatment of Nocturia: A Double-Blind, Placebo-Controlled Study

2007

Objectives: To investigate efficacy, safety, and impact on quality of sleep of desmopressin in the treatment of nocturia. Methods: Adults aged >= 18 yr with nocturia (>= 2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period. Patients should show sufficient response during the dose-titration period (>= 20% reduction in nocturnal diuresis) and a return of nocturnal diuresis to >= 80% of baseline levels during washout. Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo. Results: 127 patients were randomised to either desmopressin (n = 61) or placebo (n = 66). Twenty (33%) desmopressin-…

AdultMaleNephrologymedicine.medical_specialtyUrologyPlacebo-controlled studyAdministration OralDiuresisPlaceboDouble-Blind MethodInternal medicinemedicineHumansNocturiaDeamino Arginine VasopressinDesmopressinAdverse effectAgedAged 80 and overDose-Response Relationship Drugbusiness.industryAntidiuretic AgentsMiddle AgedSurgeryUrodynamicsTreatment OutcomeAnesthesiaFemaleNocturiamedicine.symptomSleepbusinesshormones hormone substitutes and hormone antagonistsFollow-Up Studiesmedicine.drugAntidiureticEuropean Urology
researchProduct

Neural dynamics of learning sound-action associations.

2008

A motor component is pre-requisite to any communicative act as one must inherently move to communicate. To learn to make a communicative act, the brain must be able to dynamically associate arbitrary percepts to the neural substrate underlying the pre-requisite motor activity. We aimed to investigate whether brain regions involved in complex gestures (ventral pre-motor cortex, Brodmann Area 44) were involved in mediating association between novel abstract auditory stimuli and novel gestural movements. In a functional resonance imaging (fMRI) study we asked participants to learn associations between previously unrelated novel sounds and meaningless gestures inside the scanner. We use functio…

AdultMaleNeural substratelcsh:MedicineBiologyBrain mapping050105 experimental psychologyAssociation03 medical and health sciences0302 clinical medicineMental ProcessesNeuroscience/Motor SystemsHumansLearningSpeech0501 psychology and cognitive sciencesAssociation (psychology)lcsh:ScienceNeuroscience/Cognitive NeuroscienceBrain MappingMultidisciplinaryBlood-oxygen-level dependentGesturesWorking memory05 social scienceslcsh:RPsychophysiological InteractionBrodmann area 44BrainMagnetic Resonance ImagingNeuroscience/Experimental PsychologySoundAcoustic StimulationFemalelcsh:Q030217 neurology & neurosurgeryPsychomotor PerformanceCognitive psychologyGestureResearch ArticlePLoS ONE
researchProduct

Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam Three Times a Day: A Randomized Controlled Multicenter Trial in Patients with…

2004

A prospective, randomized, controlled multicenter trial was performed to evaluate the efficacy and safety of once-daily oral monotherapy with 500 mg levofloxacin in comparison with 4.5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia. Low risk was defined by oral temperatureor = 38.5 degrees C on one occasion oror = 38.0 degrees C twice within 24 hours and granulocytopeniaor = 500/microL for less than 10 days. The primary end point was defined as defervescence after 72 hours followed by at least 7 afebrile days. Secondary end points were overall response, time to defervescence, survival on day 30, and toxicity. Thirty-four episodes were included. Fever o…

AdultMaleOfloxacinTazobactammedicine.medical_specialtyNeutropeniaFeverAdministration OralPenicillanic AcidAntineoplastic AgentsLevofloxacinNeutropeniaFever of Unknown OriginTazobactamDrug Administration ScheduleImmunocompromised HostLevofloxacinNeoplasmsInternal medicineMulticenter trialHumansMedicineProspective StudiesAgedAntibacterial agentPiperacillinbusiness.industryBacterial InfectionsHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomePiperacillin/tazobactamDrug Therapy CombinationFemaleDisease SusceptibilitySafetybusinessFebrile neutropeniaPiperacillinmedicine.drugInternational Journal of Hematology
researchProduct

Subchronic Effects of Olanzapine on Sleep EEG in Schizophrenic Patients with Predominantly Negative Symptoms

2004

Background It is well known that sleep disturbance is an integral symptom of schizophrenia. In recent studies, a deficit of delta sleep has been observed in schizophrenic patients. Antipsychotic drugs with serotonin (5-HT2) receptor-antagonistic properties are considered to have delta sleep promoting effects. We have investigated the effects of subchronic olanzapine treatment on sleep EEG in schizophrenic patients. Methods The effects of administration of olanzapine (15 to 20 mg) on sleep were studied for four weeks in 10 male, drug-free patients suffering from schizophrenia with predominantly negative symptoms. Conventional sleep EEG parameters were investigated at baseline and after treat…

AdultMaleOlanzapineAdolescentPolysomnographymedicine.medical_treatmentPolysomnographySeverity of Illness IndexDrug Administration ScheduleBenzodiazepinesSurveys and QuestionnairesmedicineHumansPharmacology (medical)AntipsychoticSleep disorderSleep Stagesmedicine.diagnostic_testElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseSleep in non-human animalsDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthDelta RhythmOlanzapineSchizophreniaAnesthesiaDelta RhythmSchizophreniaSchizophrenic PsychologySleep StagesPsychologyAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

2009

Purpose Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of temsirolimus in comparison with investigator's choice single-agent therapy in relapsed or refractory disease. Patients and Methods In this multicenter, open-label, phase III study, 162 patients with relapsed or refractory MCL were randomly assigned (1:1:1) to receive one of two temsirolimus regimens: 175 mg weekly for 3 weeks followed by either 75 mg (175/75-mg) or 25 mg (175/25-mg) weekly, or investigator's choice therapy from prospectively approved options. The primary end point was progression-free survival (P…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAntineoplastic AgentsKaplan-Meier EstimateLymphoma Mantle-CellDisease-Free SurvivalDrug Administration ScheduleRidaforolimuschemistry.chemical_compoundRefractoryRecurrenceInternal medicinemedicineHumansProspective StudiesProtein Kinase InhibitorsAgedNeoplasm StagingAged 80 and overSirolimusbusiness.industryLymphoma Non-HodgkinTOR Serine-Threonine KinasesMiddle Agedmedicine.diseaseTemsirolimusSurgeryFludarabineOncologychemistryDrug Resistance NeoplasmSirolimusRefractory Mantle Cell LymphomaFemaleRituximabMantle cell lymphomabusinessProtein Kinasesmedicine.drugJournal of Clinical Oncology
researchProduct

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a p…

2008

This is a phase II institutional exploratory trial of biweekly irinotecan and cetuximab administration regimen in metastatic colorectal cancer patients progressing to at least one previous chemotherapy line. A total of 40 patients were treated between November 2005 and November 2007 with irinotecan 180 mg m−2 and cetuximab 500 mg m−2 q2w (every 2 weeks), in every 21-day cycles, until unacceptable toxicity or progressive disease. An overall response rate of 22.5% was obtained (two complete and seven partial responses). The disease control rate was 60%. The time to progression was 3.4 months and the overall survival was 8 months. The toxicity compared very favourably to weekly cetuximab combi…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCetuximabAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineHumansProspective StudiesNeoplasm MetastasisAdverse effectAgedChemotherapyCetuximabbusiness.industrymetastatic colorectal cancerbiweekly scheduleAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryClinical trialIrinotecanRegimenOncologyCamptothecinFemaleColorectal NeoplasmsbusinessProgressive diseasemedicine.drugBritish Journal of Cancer
researchProduct